Bio-Path Holdings, Inc. (BPTH)
- Previous Close
2.6350 - Open
2.6400 - Bid 2.6000 x 100
- Ask 2.7500 x 100
- Day's Range
2.5000 - 2.7800 - 52 Week Range
2.3500 - 44.8000 - Volume
117,148 - Avg. Volume
1,424,576 - Market Cap (intraday)
4.195M - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-33.6300 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
40.00
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
www.biopathholdings.comRecent News: BPTH
Performance Overview: BPTH
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BPTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BPTH
Valuation Measures
Market Cap
4.20M
Enterprise Value
3.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.21
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-103.19%
Return on Equity (ttm)
-220.02%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-16.08M
Diluted EPS (ttm)
-33.6300
Balance Sheet and Cash Flow
Total Cash (mrq)
1.05M
Total Debt/Equity (mrq)
25.62%
Levered Free Cash Flow (ttm)
-5.52M